Real-world analysis evaluates the changes in FRα expression during secondary debulking surgery in ovarian cancer patients, suggesting clinical relevance.
FRα is a clinically actionable target in ovarian cancer, with mirvetuximab soravtansine approved in patients with high expression based on PS2 scoring. However, FRα expression may be heterogeneous and dynamic. Real-world data on FRα expression patterns and their clinical implications remain limited We evaluated temporal changes in FRα expression between primary and secondary debulking surgery (SDS).
No takes yet. Share an insight, caveat, or question.
Liontos et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: